secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001837607-24-000070
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma stockholders elect two Class I directors and approve potential Daewoong issuance at annual meeting
--------------------------------------------------------------------------------

- Robert Palmisano and Shelley Thunen elected as Class I directors for three-year terms ending 2027.
- Stockholders approved potential issuance of 20%+ of Class A common stock to Daewoong Pharmaceuticals at below-market value, a change-of-control measure.
- Ratification of KPMG LLP as auditor for fiscal 2024 passed with 25,491,112 votes for.
- All three proposals received sufficient votes; broker non-votes were 675,301 on first two proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000070/0001837607-24-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000070/aeon-20240614x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer